Search

Your search keyword '"Taramasso, L."' showing total 285 results

Search Constraints

Start Over You searched for: Author "Taramasso, L." Remove constraint Author: "Taramasso, L."
285 results on '"Taramasso, L."'

Search Results

1. TD-1 Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study

2. Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine

Catalog

Books, media, physical & digital resources

3. Central nervous system and neuropsychiatric adverse events in Women living with HIV treated with INSTI-based regimens

4. Lipids, weight gain and body mass index in ARV experienced PLWH treated with doravirine-based treatments: a comparison between dual or triple regimens vs bictegravir based triple regimen

5. Changes in body mass index and lipid profile in PWH switching to a regimen without TAF vs PWH continuing TAF. Data from a real-life setting

6. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects

7. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

8. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

9. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study

10. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

12. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

14. Pillars of long-term antiretroviral therapy success

15. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

16. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

17. Incident diabetes in course of antiretroviral therapy

18. Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda

19. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

20. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

22. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children

23. Weight Gain: A Possible Side Effect of All Antiretrovirals

24. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

25. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

26. Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia

27. Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study

28. Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19

29. Reversibility of Central Nervous System Adverse Events in Course of Art

30. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

31. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

32. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

33. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

34. The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study

36. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

37. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

38. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study

39. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

41. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity

42. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani

43. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

44. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

45. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

46. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

47. Factors associated with hospital admission for COVID-19 in HIV patients

49. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

50. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort